Figure 2.

The CD3 patient subgroup had faster disease recurrence and there was a trend towards a shorter time to second surgery compared with the CD1 subgroup. [A] The survival analysis [Gehan–Breslow–Wilcoxon test] using time from first surgery to recurrence or last follow-up indicated that the proportion of recurrence-free survival in the CD3 cluster was smaller than in the CD1 subgroup [p = 0.02, median survival time [months], CD1 = 10, CD2 = 8, and CD3 = 6. [B] Using time from first to second surgery or last follow-up within 5 years indicated a greater proportion of patients being without a second surgery in CD1 compared with those in CD3 [marginally significant, p = 0.08] in the combined cohort of SB139.